SCHEMBL2236309

SCHEMBL2236309

CN1CCC(N2CCN(c3ccc([NH])cc3)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 5/20 0.53
L3MBTL1 Q9Y468 5/20 0.53
ALDH1A1 P00352 2/20 0.52
KMT2A Q03164 4/20 0.50
GRIN2B Q13224 1/20 0.49
MAPT P10636 2/20 0.46
MBTD1 Q05BQ5 2/20 0.45
MEN1 O00255 2/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ADRA2C P18825 1/20 0.44
GFER P55789 1/20 0.44
PTK2B Q14289 1/20 0.44
ESR2 Q92731 1/20 0.44
TP53BP1 Q12888 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12082195 0.85 L3MBTL3 (0.55) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL28506443 0.83 L3MBTL3 (0.53) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL156523 0.83 MAPT (0.68) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL23422581 0.83 L3MBTL3 (0.53) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL13200798 0.83 GRIN2B (0.70) L3MBTL3L3MBTL1ALDH1A1GRIN2BMAPT
SCHEMBL574836 0.82 MAPT (0.63) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL19718448 0.81 KMT2A (0.55) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL14923967 0.81 KMT2A (0.51) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL14850179 0.81 ALDH1A1 (0.57) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B
SCHEMBL27879361 0.80 L3MBTL3 (0.53) L3MBTL3L3MBTL1ALDH1A1KMT2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 L3MBTL3 1491/4885L3MBTL1 1334/4885ALDH1A1 3711/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 L3MBTL3 1491/4885L3MBTL1 1334/4885ALDH1A1 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.